Artificial intelligence-driven new drug development, which aims to maximize R&D efficiency, has emerged as a key future strategy for South Korean pharma firms, as the huge time and cost required to discover and develop new drugs serves as a major barrier for domestic players.
Although Korean companies have been actively securing AI technology through partnerships over the past few years, their progress has been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?